VVY Vivoryon Therapeutics N.V.

0.7035USD0.6400 EUR · AMS-3.32%Mkt Cap: 20.83M USDP/E: —

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-…

Key Statistics

Company
Market Cap20.83M USD
Enterprise Value18.23M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-9.73M USD
Revenue/Share—
Last Price0.7035 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINNL00150002Q7
Valuation
P/E (Trailing)—
P/E (Forward)-2.06
PEG—
EV/EBITDA-2.47
EV/Revenue—
P/S—
P/B12.08
EPS (TTM)-0.25 USD
EPS (Forward)-0.34 USD
52W Range
0.587010% of range1.811
52W High1.811 USD
52W Low0.5870 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-187.29%
ROA-117.76%
ROIC—
ROCE-133.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.29M USD
CapEx (TTM)6.60K USD
FCF Margin—
FCF Yield-19.82%
Net Debt-2.61M USD
Net Debt/EBITDA0.35
Net Debt/FCF—
Balance Sheet
Debt/Equity0.02
Current Ratio4.56
Quick Ratio4.03
Book Value/Sh0.06 USD
Cash/Share0.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.530 USD
Upside (mean)+970.3%
Target Range7.530 USD – 7.530 USD
# Analysts1
Ownership
Shares Out.29.61M
Float26.35M
Insiders4.85%
Institutions8.85%
Technical
SMA 501.038 (-32.2%)
SMA 2001.286 (-45.3%)
Beta1.45
S&P 52W Chg12.00%
Avg Vol (30d)106.56K
Avg Vol (10d)180.88K
Technical Indicators
RSI (14)35.1
MACD-0.0736
MACD Signal-0.0760
MACD Hist.+0.0025
BB Upper1.029 USD
BB Middle0.8258 USD
BB Lower0.6225 USD
BB Width49.24%
ATR (14)0.0724 USD
Vol Ratio (20d)0.09x

About Vivoryon Therapeutics (AMS: VVY)

›

Vivoryon Therapeutics (AMS: VVY) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.

The shares were at 0.6400 EUR on 19 November 2026, down 60.6% over 52 weeks. Its 52-week range is 0.5340 EUR to 1.648 EUR: the price is 61.2% below the high and 19.9% above the low.

Its market capitalisation is 18.95M EUR.

Vivoryon Therapeutics reports return on equity of -187.3% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 2.37M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 22 April 2027.